|
发表于 2009-5-20 02:11 PM
|
显示全部楼层
本帖最后由 wustler 于 2009-5-20 15:25 编辑
24# wower
I think at this time, the date of decision is still speculative. The March PR and the latest PR do have different wordings. But it's not definitive on the possible scenarios that's why the pps bounced back almost 50% from the lows and stayed at .3x.
What I am thinking is that because the going concern of ACUS, they don't wanna do additional clinical trial and that's why they submitted the amended plan. Since this drug is very promising, FDA may want to push it for the broad use, pure speculation, to discuss the design of new trials.
I speculate, is it possible that FDA will prove the narrow use to give the company enough wiggle room to carry out the new trials for broad use?
xxtrader, do you think it's possible? |
|